SCHEMBL4111182

SCHEMBL4111182

COc1cccc(C(=O)c2cc(F)ccc2N)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.49
KEAP1 Q14145 1/20 0.49
GAA P10253 3/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
RELA Q04206 1/20 0.46
TUBB4A P04350 2/20 0.45
TUBB P07437 2/20 0.45
TUBA3C P0DPH7 2/20 0.45
TUBA1B P68363 2/20 0.45
TUBA4A P68366 2/20 0.45
TUBB4B P68371 2/20 0.45
TUBB3 Q13509 2/20 0.45
TUBB2A Q13885 2/20 0.45
TUBB8 Q3ZCM7 2/20 0.45
TUBA3E Q6PEY2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118069 0.90 MAPK14 (0.51) MAPK14GAAKMT2AHSD17B10NPC1
SCHEMBL4126866 0.86 KEAP1 (0.49) MAPK14KEAP1HSD17B10NPC1RAB9A
SCHEMBL4124280 0.86 ATM (0.51) GAAKMT2AHSD17B10NPC1RAB9A
SCHEMBL635552 0.84 RECQL (0.56) MAPK14GAAKMT2AHSD17B10NPC1
SCHEMBL4117593 0.84 MAPT (0.50) GAAKMT2AHSD17B10NPC1RAB9A
SCHEMBL8176832 0.84 MAPK14 (0.58) MAPK14GAAKMT2ANPC1RAB9A
SCHEMBL13775820 0.84 RORB (0.48) GAAKMT2AHSD17B10LMNAL3MBTL1
SCHEMBL3762150 0.83 RAB9A (0.55) GAAKMT2AHSD17B10NPC1RAB9A
SCHEMBL8467508 0.78 RAB9A (0.52) GAAKMT2AHSD17B10NPC1RAB9A
SCHEMBL8181985 0.78 CES2 (0.49) GAAKMT2AHSD17B10NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR MAPK14 4368/4885KEAP1 427/4885GAA 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.